Two Sigma Advisers LP Grows Stock Holdings in Sana Biotechnology, Inc. (NASDAQ:SANA)

Two Sigma Advisers LP boosted its holdings in shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 677.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 209,000 shares of the company's stock after purchasing an additional 182,100 shares during the period. Two Sigma Advisers LP owned about 0.09% of Sana Biotechnology worth $341,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. SG Americas Securities LLC purchased a new position in shares of Sana Biotechnology during the fourth quarter valued at approximately $239,000. Millennium Management LLC increased its position in Sana Biotechnology by 604.8% during the 4th quarter. Millennium Management LLC now owns 728,901 shares of the company's stock valued at $1,188,000 after purchasing an additional 625,481 shares during the period. Charles Schwab Investment Management Inc. increased its position in Sana Biotechnology by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,056,512 shares of the company's stock valued at $1,722,000 after purchasing an additional 8,666 shares during the period. Geode Capital Management LLC raised its holdings in Sana Biotechnology by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company's stock worth $5,206,000 after purchasing an additional 26,601 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Sana Biotechnology by 44.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,557,496 shares of the company's stock worth $2,538,000 after purchasing an additional 478,596 shares during the period. Institutional investors own 88.23% of the company's stock.

Sana Biotechnology Stock Down 0.4%

Shares of NASDAQ SANA traded down $0.01 during midday trading on Monday, hitting $2.83. The stock had a trading volume of 3,710,819 shares, compared to its average volume of 3,532,832. The business's 50 day moving average is $1.84 and its 200-day moving average is $2.33. Sana Biotechnology, Inc. has a 52 week low of $1.26 and a 52 week high of $7.40. The company has a market cap of $638.10 million, a P/E ratio of -2.02 and a beta of 1.78.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.02. As a group, analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Sana Biotechnology in a research note on Friday, March 14th. They issued a "buy" rating and a $7.00 price target for the company. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 target price for the company in a research report on Tuesday, March 18th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $11.00 price target on shares of Sana Biotechnology in a research note on Thursday, April 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $10.80.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.